Bioline RX Stock Price, News & Analysis (NASDAQ:BLRX)

$1.09 -0.01 (-0.91 %)
(As of 12/13/2017 11:54 AM ET)
Previous Close$1.10
Today's Range$1.07 - $1.11
52-Week Range$0.80 - $1.38
Volume554,400 shs
Average Volume490,349 shs
Market Capitalization$115.09 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89

About Bioline RX (NASDAQ:BLRX)

Bioline RX logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-2548-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio10.12%
Quick Ratio10.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book1.79

Profitability

Trailing EPS($0.33)
Net Income$-15,840,000.00
Net MarginsN/A
Return on Equity-47.20%
Return on Assets-42.23%

Miscellaneous

Employees43
Outstanding Shares104,630,000

Bioline RX (NASDAQ:BLRX) Frequently Asked Questions

What is Bioline RX's stock symbol?

Bioline RX trades on the NASDAQ under the ticker symbol "BLRX."

How were Bioline RX's earnings last quarter?

Bioline RX Ltd (NASDAQ:BLRX) issued its earnings results on Thursday, August, 11th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). View Bioline RX's Earnings History.

When will Bioline RX make its next earnings announcement?

Bioline RX is scheduled to release their next quarterly earnings announcement on Thursday, March, 22nd 2018. View Earnings Estimates for Bioline RX.

Where is Bioline RX's stock going? Where will Bioline RX's stock price be in 2017?

5 Wall Street analysts have issued twelve-month price objectives for Bioline RX's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Bioline RX's stock price to reach $3.20 in the next year. View Analyst Ratings for Bioline RX.

What are Wall Street analysts saying about Bioline RX stock?

Here are some recent quotes from research analysts about Bioline RX stock:

  • 1. Maxim Group analysts commented, "BiolineRx announced long-term follow-up data from the phase 2a study of BL-8040 (CXCR4 antagonist) in relapsed/refractory acute myeloid leukemia (r/ r AML) demonstrating improved overall survival (OS)." (12/4/2017)
  • 2. HC Wainwright analysts commented, "AML Needle Continues to Point in Right Direction; Reiterate Buy Responses appear to impact survival in relapsed or refractory setting. This morning, BioLineRx announced long-term follow-up data from the BL-8040 Phase 2a in relapsed or refractory AML. Recall that in March 2016, topline results (n=42) were presented showing an overall response rate (CR+CRi) of 38%, which compared favorably to a historical control of approximately 20% (HiDAC alone). With longer observation in hand, the company is highlighting data from 16 patients in the expansion phase of the study: 1) median follow-up time of 338 days (29-853 days); 2) median overall survival of 11.1 months; and 3) estimated one- and two-year survival rates of 37.5% and 28.5%, respectively. While these patient numbers continue to be small, they continue to compare favorably with the expected overall survival of 6.1 months for HiDAC." (12/4/2017)
  • 3. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (11/27/2017)

Who are some of Bioline RX's key competitors?

Who are Bioline RX's key executives?

Bioline RX's management team includes the folowing people:

  • Aharon Schwartz Ph.D., Chairman of the Board (Age 75)
  • Philip Adam Serlin, Chief Executive Officer (Age 56)
  • Mali Zeevi, Chief Financial Officer
  • Merril Gersten, Chief Scientific Officer
  • Moshe Phillip M.D., Vice President of Medical Affairs and Senior Clinical Advisor (Age 59)
  • David Malek, Vice President - Business Development (Age 35)
  • Leah Klapper, General Manager, BioLine Innovations Jerusalem (Age 1)
  • Michael J. Anghel, Director (Age 78)
  • Jacob Friedman, Director (Age 44)
  • Raphael Hofstein, Director (Age 63)

How do I buy Bioline RX stock?

Shares of Bioline RX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioline RX's stock price today?

One share of Bioline RX stock can currently be purchased for approximately $1.09.

How big of a company is Bioline RX?

Bioline RX has a market capitalization of $115.09 million. The biotechnology company earns $-15,840,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Bioline RX employs 43 workers across the globe.

How can I contact Bioline RX?

Bioline RX's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]


MarketBeat Community Rating for Bioline RX (BLRX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Bioline RX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioline RX (NASDAQ:BLRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.85$2.85$2.85$3.44
Price Target Upside: 154.46% upside151.10% upside174.04% upside309.33% upside

Bioline RX (NASDAQ:BLRX) Consensus Price Target History

Price Target History for Bioline RX (NASDAQ:BLRX)

Bioline RX (NASDAQ:BLRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/4/2017OppenheimerSet Price TargetBuy$3.00LowView Rating Details
12/4/2017Maxim GroupSet Price TargetBuy$3.00LowView Rating Details
12/4/2017HC WainwrightSet Price TargetBuy$4.00HighView Rating Details
8/9/2017Roth CapitalSet Price TargetBuy$3.00LowView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Bioline RX (NASDAQ:BLRX) Earnings History and Estimates Chart

Earnings by Quarter for Bioline RX (NASDAQ:BLRX)

Bioline RX (NASDAQ BLRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2018        
8/8/20176/30/2017($0.05)($0.05)$0.01 millionViewListenView Earnings Details
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Bioline RX (NASDAQ:BLRX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.05)($0.05)($0.05)
Q4 20171($0.05)($0.05)($0.05)
Q1 20181($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bioline RX (NASDAQ:BLRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bioline RX (NASDAQ BLRX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Bioline RX (NASDAQ BLRX) News Headlines

Source:
DateHeadline
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY - PR Newswire (press release)BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY - PR Newswire (press release)
www.prnewswire.com - December 7 at 5:27 PM
BioLineRx (BLRX) Announces Positive Overall Survival Results From LT Follow-up of Phase 2a Trial in r/r AML - StreetInsider.comBioLineRx (BLRX) Announces Positive Overall Survival Results From LT Follow-up of Phase 2a Trial in r/r AML - StreetInsider.com
www.streetinsider.com - December 6 at 5:04 PM
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NYBioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
finance.yahoo.com - December 5 at 10:30 AM
Bioline RX (BLRX) PT Set at $3.00 by OppenheimerBioline RX (BLRX) PT Set at $3.00 by Oppenheimer
www.americanbankingnews.com - December 4 at 5:22 PM
Bioline RX (BLRX) Stock Rating Reaffirmed by Maxim GroupBioline RX (BLRX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 4 at 12:30 PM
Bioline RX (BLRX) Given a $4.00 Price Target at HC WainwrightBioline RX (BLRX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 4 at 11:38 AM
BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AMLBioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
finance.yahoo.com - December 4 at 9:49 AM
BioLineRx Ltd. (BLRX) Expected to Announce Earnings of -$0.07 Per ShareBioLineRx Ltd. (BLRX) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - November 28 at 5:14 AM
BioLineRx Ltd. (BLRX) Lowered to Sell at Zacks Investment ResearchBioLineRx Ltd. (BLRX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 27 at 8:26 PM
FY2021 Earnings Forecast for BioLineRx Ltd. Issued By Oppenheimer Holdings (BLRX)FY2021 Earnings Forecast for BioLineRx Ltd. Issued By Oppenheimer Holdings (BLRX)
www.americanbankingnews.com - November 23 at 10:35 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 ... - PR Newswire (press release)BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 ... - PR Newswire (press release)
www.prnewswire.com - November 21 at 3:33 PM
BioLineRx Reports Third Quarter 2017 Financial ResultsBioLineRx Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 21 at 3:33 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers SymposiumBioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - November 20 at 5:51 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers SymposiumBioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - November 20 at 5:51 PM
BioLineRx Ltd. (BLRX) Receives Average Recommendation of "Buy" from AnalystsBioLineRx Ltd. (BLRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 19 at 8:02 PM
BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New YorkBioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York
finance.yahoo.com - November 16 at 12:04 PM
BioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on TuesdayBioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 14 at 2:30 AM
BioLineRx to Report Third Quarter 2017 Results on November 21, 2017BioLineRx to Report Third Quarter 2017 Results on November 21, 2017
finance.yahoo.com - November 9 at 5:47 PM
Zacks: Analysts Anticipate BioLineRx Ltd. (BLRX) Will Post Earnings of -$0.05 Per ShareZacks: Analysts Anticipate BioLineRx Ltd. (BLRX) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - November 9 at 1:44 PM
BioLineRx Announces Oral Presentation at ASH of Data Supporting ... - PR Newswire (press release)BioLineRx Announces Oral Presentation at ASH of Data Supporting ... - PR Newswire (press release)
www.prnewswire.com - November 2 at 10:15 PM
BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term EngraftmentBioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
finance.yahoo.com - November 2 at 5:14 PM
BioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by BrokeragesBioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 9:34 PM
-$0.05 Earnings Per Share Expected for BioLineRx Ltd. (BLRX) This Quarter-$0.05 Earnings Per Share Expected for BioLineRx Ltd. (BLRX) This Quarter
www.americanbankingnews.com - October 20 at 8:30 PM
BioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under ... - StreetInsider.comBioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under ... - StreetInsider.com
www.streetinsider.com - October 18 at 10:54 PM
Head to Head Survey: BioLineRx (BLRX) and Its CompetitorsHead to Head Survey: BioLineRx (BLRX) and Its Competitors
www.americanbankingnews.com - October 18 at 10:22 PM
BioLineRx Ltd. (BLRX) Given a $4.00 Price Target by HC Wainwright AnalystsBioLineRx Ltd. (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 18 at 8:22 PM
BioLineRx Ltd. (BLRX) PT Set at $3.00 by Oppenheimer Holdings, Inc.BioLineRx Ltd. (BLRX) PT Set at $3.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 18 at 7:08 PM
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy CollaborationBioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
finance.yahoo.com - October 18 at 5:53 PM
-$0.05 EPS Expected for BioLineRx Ltd. (BLRX) This Quarter-$0.05 EPS Expected for BioLineRx Ltd. (BLRX) This Quarter
www.americanbankingnews.com - October 2 at 12:20 AM
BioLineRx Ltd. (BLRX) Given Consensus Rating of "Buy" by BrokeragesBioLineRx Ltd. (BLRX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 30 at 8:34 PM
BioLineRx Ltd. (BLRX) Receives Buy Rating from HC WainwrightBioLineRx Ltd. (BLRX) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - September 28 at 8:00 AM
Contrasting BioLineRx (BLRX) & Its RivalsContrasting BioLineRx (BLRX) & Its Rivals
www.americanbankingnews.com - September 26 at 8:22 PM
BioLineRx (BLRX) Reports Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration - StreetInsider.comBioLineRx (BLRX) Reports Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration - StreetInsider.com
www.streetinsider.com - September 26 at 8:11 AM
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy CollaborationBioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
finance.yahoo.com - September 26 at 8:11 AM
Spectrum Pharmaceuticals (SPPI) versus BioLineRx (BLRX) Critical AnalysisSpectrum Pharmaceuticals (SPPI) versus BioLineRx (BLRX) Critical Analysis
www.americanbankingnews.com - September 23 at 4:20 PM
BioLineRx Ltd. (BLRX) Given Buy Rating at Oppenheimer Holdings, Inc.BioLineRx Ltd. (BLRX) Given Buy Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 17 at 10:22 PM
BioLineRx Ltd. (BLRX) Short Interest UpdateBioLineRx Ltd. (BLRX) Short Interest Update
www.americanbankingnews.com - September 16 at 1:44 AM
Brokers Set Expectations for BioLineRx Ltd.s FY2021 Earnings (BLRX)Brokers Set Expectations for BioLineRx Ltd.'s FY2021 Earnings (BLRX)
www.americanbankingnews.com - September 13 at 4:46 PM
 Analysts Expect BioLineRx Ltd. (BLRX) Will Announce Earnings of -$0.05 Per Share Analysts Expect BioLineRx Ltd. (BLRX) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - September 13 at 6:18 AM
BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New YorkBioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
finance.yahoo.com - September 7 at 4:49 PM
BioLineRx Ltd. (BLRX) Given Average Rating of "Buy" by BrokeragesBioLineRx Ltd. (BLRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 11:00 PM
BioLineRx Ltd. (BLRX) Short Interest Up 49.6% in AugustBioLineRx Ltd. (BLRX) Short Interest Up 49.6% in August
www.americanbankingnews.com - August 28 at 1:48 AM
MOLOGEN AG and Chinese iPharma Ltd. signed binding term sheet for a collaboration regarding the development, manufacture and commercialization of lefitolimod in China and a ...MOLOGEN AG and Chinese iPharma Ltd. signed binding term sheet for a collaboration regarding the development, manufacture and commercialization of lefitolimod in China and a ...
www.businesswire.com - August 25 at 6:20 PM
BioLineRx Moves a Regulatory Submission for BL-8040 Trial - NasdaqBioLineRx Moves a Regulatory Submission for BL-8040 Trial - Nasdaq
www.nasdaq.com - August 22 at 10:16 PM
BioLineRx Moves a Regulatory Submission for BL-8040 TrialBioLineRx Moves a Regulatory Submission for BL-8040 Trial
www.zacks.com - August 22 at 5:15 PM
BioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD - StreetInsider.comBioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD - StreetInsider.com
www.streetinsider.com - August 21 at 9:36 PM
BioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSDBioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD
www.streetinsider.com - August 21 at 4:34 PM
BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell MobilizationBioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
finance.yahoo.com - August 21 at 4:34 PM
BioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by AnalystsBioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 11 at 11:32 PM
Oppenheimer Holdings Comments on BioLineRx Ltd.s Q3 2017 Earnings (NASDAQ:BLRX)Oppenheimer Holdings Comments on BioLineRx Ltd.'s Q3 2017 Earnings (NASDAQ:BLRX)
www.americanbankingnews.com - August 11 at 9:48 AM

SEC Filings

Bioline RX (NASDAQ:BLRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioline RX (NASDAQ:BLRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioline RX (NASDAQ BLRX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.